ARTV – artiva biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
Artiva Biotherapeutics (NASDAQ:ARTV) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability
Artiva Biotherapeutics: Upcoming Data Presentations May Bring Them Out Of Being Ignored [Seeking Alpha]
Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
Form 4 Artiva Biotherapeutics, For: Dec 15 Filed by: Aslan Fred
Form 144 Artiva Biotherapeutics, Filed by: Aslan Fred
Form 4 Artiva Biotherapeutics, For: Dec 12 Filed by: Horan Christopher
Form 4 Artiva Biotherapeutics, For: Dec 12 Filed by: Raymon Heather
Form 4 Artiva Biotherapeutics, For: Dec 12 Filed by: Bush Jennifer
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.